Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.

Literature DB >> 22624832

Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.

Rakesh C Kukreja¹, Fadi N Salloum, Anindita Das.

Abstract

Cyclic guanosine monophosphate (cGMP) is an important intracellular second messenger that mediates multiple tissue and cellular responses. The cGMP pathway is a key element in the pathophysiology of the heart and its modulation by drugs such as phosphodiesterase (PDE)-5 inhibitors and guanylate cyclase activators may represent a promising therapeutic approach for acute myocardial infarction, cardiac hypertrophy, heart failure, and doxorubicin cardiotoxicity in patients. In addition, PDE-5 inhibitors may prove to be innovative therapeutic agents for enhancing the chemosensitivity of doxorubicin while providing concurrent cardiac benefit.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2012 PMID： 22624832 PMCID： PMC4230443 DOI： 10.1016/j.jacc.2011.09.086

Source DB: PubMed Journal: J Am Coll Cardiol ISSN： 0735-1097 Impact factor: 24.094

67 in total

1. NO activation of guanylyl cyclase.

Authors: Michael Russwurm; Doris Koesling
Journal: EMBO J Date: 2004-10-28 Impact factor: 11.598

Review 2. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors: Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal: Nat Rev Drug Discov Date: 2006-09 Impact factor: 84.694

Review 3. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use.

Authors: Andrew T Bender; Joseph A Beavo
Journal: Pharmacol Rev Date: 2006-09 Impact factor: 25.468

4. Cyclic GMP-dependent protein kinase Ialpha attenuates necrosis and apoptosis following ischemia/reoxygenation in adult cardiomyocyte.

Authors: Anindita Das; Albert Smolenski; Suzanne M Lohmann; Rakesh C Kukreja
Journal: J Biol Chem Date: 2006-10-12 Impact factor: 5.157

5. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells.

Authors: Bing Zhu; Lakshmi Vemavarapu; W Joseph Thompson; Samuel J Strada
Journal: J Cell Biochem Date: 2005-02-01 Impact factor: 4.429

6. Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits.

Authors: Fadi N Salloum; Yuko Takenoshita; Ramzi A Ockaili; Vladimir P Daoud; Eric Chou; Kazu-ichi Yoshida; Rakesh C Kukreja
Journal: J Mol Cell Cardiol Date: 2006-12-08 Impact factor: 5.000

Review 7. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling.

Authors: D S Burley; P Ferdinandy; G F Baxter
Journal: Br J Pharmacol Date: 2007-08-13 Impact factor: 8.739

8. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice.

Authors: Fadi N Salloum; Antonio Abbate; Anindita Das; Jon-Erik Houser; Colin A Mudrick; Ian Z Qureshi; Nicholas N Hoke; Sion K Roy; William R Brown; Shashi Prabhakar; Rakesh C Kukreja
Journal: Am J Physiol Heart Circ Physiol Date: 2008-01-25 Impact factor: 4.733

9. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.

Authors: Jayan Nagendran; Stephen L Archer; Daniel Soliman; Vikram Gurtu; Rohit Moudgil; Alois Haromy; Chantal St Aubin; Linda Webster; Ivan M Rebeyka; David B Ross; Peter E Light; Jason R B Dyck; Evangelos D Michelakis
Journal: Circulation Date: 2007-07-02 Impact factor: 29.690

10. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism.

Authors: Eiki Takimoto; Hunter C Champion; Diego Belardi; Javid Moslehi; Marco Mongillo; Evanthia Mergia; David C Montrose; Takayoshi Isoda; Kate Aufiero; Manuela Zaccolo; Wolfgang R Dostmann; Carolyn J Smith; David A Kass
Journal: Circ Res Date: 2004-12-02 Impact factor: 17.367

30 in total

1. Association analyses based on false discovery rate implicate new loci for coronary artery disease.

Authors: Christopher P Nelson; Anuj Goel; Adam S Butterworth; Stavroula Kanoni; Tom R Webb; Eirini Marouli; Lingyao Zeng; Ioanna Ntalla; Florence Y Lai; Jemma C Hopewell; Olga Giannakopoulou; Tao Jiang; Stephen E Hamby; Emanuele Di Angelantonio; Themistocles L Assimes; Erwin P Bottinger; John C Chambers; Robert Clarke; Colin N A Palmer; Richard M Cubbon; Patrick Ellinor; Raili Ermel; Evangelos Evangelou; Paul W Franks; Christopher Grace; Dongfeng Gu; Aroon D Hingorani; Joanna M M Howson; Erik Ingelsson; Adnan Kastrati; Thorsten Kessler; Theodosios Kyriakou; Terho Lehtimäki; Xiangfeng Lu; Yingchang Lu; Winfried März; Ruth McPherson; Andres Metspalu; Mar Pujades-Rodriguez; Arno Ruusalepp; Eric E Schadt; Amand F Schmidt; Michael J Sweeting; Pierre A Zalloua; Kamal AlGhalayini; Bernard D Keavney; Jaspal S Kooner; Ruth J F Loos; Riyaz S Patel; Martin K Rutter; Maciej Tomaszewski; Ioanna Tzoulaki; Eleftheria Zeggini; Jeanette Erdmann; George Dedoussis; Johan L M Björkegren; Heribert Schunkert; Martin Farrall; John Danesh; Nilesh J Samani; Hugh Watkins; Panos Deloukas
Journal: Nat Genet Date: 2017-07-17 Impact factor: 38.330

Review 2. Highlights of the year in JACC 2012.

Authors: Anthony N DeMaria; Jeroen J Bax; Gregory K Feld; Barry H Greenberg; Jennifer L Hall; Mark A Hlatky; Wilbur Y W Lew; João A C Lima; Ehtisham Mahmud; Alan S Maisel; Sanjiv M Narayan; Steven E Nissen; David J Sahn; Sotirios Tsimikas
Journal: J Am Coll Cardiol Date: 2013-01-22 Impact factor: 24.094

Review 3. Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.

Authors: Sevil Korkmaz-Icöz; Tamás Radovits; Gábor Szabó
Journal: Br J Pharmacol Date: 2017-03-23 Impact factor: 8.739

Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.

1. NO activation of guanylyl cyclase.

Review 2. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Review 3. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use.

4. Cyclic GMP-dependent protein kinase Ialpha attenuates necrosis and apoptosis following ischemia/reoxygenation in adult cardiomyocyte.

5. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells.

6. Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits.

Review 7. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling.

8. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice.

9. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.

10. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism.

1. Association analyses based on false discovery rate implicate new loci for coronary artery disease.

Review 2. Highlights of the year in JACC 2012.

Review 3. Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.

Review 4. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.

5. The effects of sildenafil citrate on urinary podocin and nephrin mRNA expression in an L-NAME model of pre-eclampsia.

6. Identification of small molecule NPR-B antagonists by high throughput screening--potential use in heart failure.

7. Insulin-like effect of the phosphodiesterase type 5 inhibitor tadalafil onto male human skeletal muscle cells.

Review 8. Hemoglobin α in the blood vessel wall.

Review 9. Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.

10. Prevention of PKG1α oxidation augments cardioprotection in the stressed heart.